Novavax Inc (NASDAQ:NVAX) shares are trading higher Thursday after the U.S. Food and Drug Administration's advisory committee voted to recommend updated vaccines for JN.1-lineage of COVID-19.
What To Know: The FDA’s committee of independent advisors voted unanimously on Wednesday to recommend that the FDA tell vaccine makers to update their COVID-19 shots to make them more effective against the JN.1 variants, per CNN.
All 16 advisors reportedly voted “yes” when asked if they recommend a “monovalent JN.1-lineage vaccine composition.” The decision now moves to the FDA.
Novavax reportedly said it’s on track to deliver the recommended vaccine by September.
In a regulatory filing, the company also announced that the FDA recently notified Novavax that it completed its filing review of the final ...